529.95
price down icon2.40%   -13.04
 
loading
Argen X Se Adr stock is traded at $529.95, with a volume of 310.32K. It is down -2.40% in the last 24 hours and up +0.48% over the past month. Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$542.99
Open:
$531.78
24h Volume:
310.32K
Relative Volume:
1.00
Market Cap:
$31.69B
Revenue:
$1.62B
Net Income/Loss:
$-204.35M
P/E Ratio:
-127.39
EPS:
-4.16
Net Cash Flow:
$-1.28B
1W Performance:
-1.15%
1M Performance:
+0.48%
6M Performance:
+36.98%
1Y Performance:
+11.19%
1-Day Range:
Value
$522.93
$543.18
1-Week Range:
Value
$522.93
$552.00
52-Week Range:
Value
$327.73
$554.74

Argen X Se Adr Stock (ARGX) Company Profile

Name
Name
Argen X Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,148
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ARGX's Discussions on Twitter

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-20-23 Downgrade Deutsche Bank Buy → Hold
Dec-20-23 Downgrade William Blair Outperform → Mkt Perform
Jul-31-23 Initiated Scotiabank Sector Perform
Jul-24-23 Downgrade UBS Buy → Neutral
Jul-17-23 Resumed Evercore ISI Outperform
Jun-15-23 Initiated Societe Generale Sell
May-31-23 Initiated UBS Buy
Apr-25-23 Initiated Citigroup Buy
Mar-14-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-07-22 Initiated William Blair Outperform
Oct-12-22 Initiated Oppenheimer Perform
Jul-29-22 Downgrade Robert W. Baird Outperform → Neutral
Jun-28-22 Resumed Stifel Buy
May-03-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Upgrade Piper Sandler Neutral → Overweight
Oct-29-21 Upgrade Guggenheim Neutral → Buy
Oct-28-21 Upgrade Raymond James Outperform → Strong Buy
Oct-07-21 Initiated Jefferies Buy
Sep-23-21 Upgrade Redburn Neutral → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-23-21 Initiated Deutsche Bank Hold
Jul-19-21 Resumed Wolfe Research Outperform
Jun-18-21 Initiated UBS Buy
Jun-04-21 Resumed Robert W. Baird Outperform
May-10-21 Upgrade H.C. Wainwright Neutral → Buy
Apr-23-21 Initiated Redburn Neutral
Mar-05-21 Reiterated H.C. Wainwright Neutral
Feb-02-21 Downgrade Piper Sandler Overweight → Neutral
Jan-04-21 Downgrade Guggenheim Buy → Neutral
Aug-25-20 Initiated Raymond James Outperform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-20 Initiated H.C. Wainwright Neutral
Feb-10-20 Initiated BofA/Merrill Buy
Nov-05-19 Initiated Credit Suisse Neutral
Oct-31-19 Upgrade William Blair Mkt Perform → Outperform
Oct-22-19 Initiated JP Morgan Overweight
Sep-27-19 Initiated Wells Fargo Market Perform
Sep-16-19 Resumed Cowen Outperform
Jun-28-19 Initiated Robert W. Baird Outperform
Jan-18-19 Resumed SunTrust Buy
Jan-04-19 Initiated Morgan Stanley Overweight
Dec-17-18 Initiated Goldman Buy
Dec-14-18 Initiated Wolfe Research Outperform
Jun-29-18 Initiated Nomura Buy
Apr-09-18 Initiated SunTrust Buy
Jan-29-18 Reiterated JMP Securities Mkt Outperform
View All

Argen X Se Adr Stock (ARGX) Latest News

pulisher
Oct 04, 2024

Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com

Oct 04, 2024
pulisher
Oct 03, 2024

Halozyme expands argenx collaboration with $30M deal - Investing.com

Oct 03, 2024
pulisher
Oct 02, 2024

Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs - Investor's Business Daily

Oct 02, 2024
pulisher
Sep 30, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 30, 2024
pulisher
Sep 25, 2024

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases - Investor's Business Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Baird sustains price target on Argenx shares, cites competition - Investing.com

Sep 25, 2024
pulisher
Sep 25, 2024

Piper Sandler maintains Overweight rating on argenx shares - Investing.com

Sep 25, 2024
pulisher
Sep 19, 2024

argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Sep 19, 2024
pulisher
Sep 06, 2024

Argen X SE ADR (ARGX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Sep 06, 2024
pulisher
Sep 06, 2024

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up - Investor's Business Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Argenx stock soars to 52-week high, hits $540.74 - Investing.com India

Sep 06, 2024
pulisher
Sep 05, 2024

Argenx stock soars to 52-week high, hits $540.74 - Investing.com

Sep 05, 2024
pulisher
Aug 29, 2024

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB - Benzinga

Aug 29, 2024
pulisher
Aug 15, 2024

Argen X SE ADR (ARGX) is looking forward to a strong quarter - SETE News

Aug 15, 2024
pulisher
Aug 10, 2024

Argenx stock hits 52-week high at $533.88 amid robust growth - Investing.com India

Aug 10, 2024
pulisher
Aug 09, 2024

Argenx stock hits 52-week high at $533.88 amid robust growth - Investing.com

Aug 09, 2024
pulisher
Aug 06, 2024

Barclays upgrades argenx stock on promising Vyvgart outlook - Investing.com

Aug 06, 2024
pulisher
Jul 30, 2024

Stocks With Rising Relative Price Strength: argenx ADR - Investor's Business Daily

Jul 30, 2024
pulisher
Jul 29, 2024

Baird raises argenx shares target on strong revenue and FDA progress - Investing.com

Jul 29, 2024
pulisher
Jul 27, 2024

Argen X SE ADR (ARGX) Outlook: Revisiting The Past For Future Insights - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Envestnet Inc. (ENV) At $62.00: Is It Worth Your Interest? - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Stevanato Group Spa (STVN) Is A Stock Worth Accumulating At Current Levels - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

The Behavior Of DXC Technology Co (DXC) Stock Is Not As Predictable As You Think - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

At $18.01 Price, Prudential plc ADR (PUK) Sits And Waits For Direction - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Analyst Stifel Price Target And Rating For HilleVax Inc (HLVX) - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Analyzing Vertex Energy Inc’s (VTNR) Stock Behavior - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Mizuho Financial Group, Inc. ADR (MFG): Be Patient, You Will Learn - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

GoPro Inc. (GPRO) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register

Jul 27, 2024
pulisher
Jul 27, 2024

Bowlero Corp (BOWL) Worth Considering For The Next Few Weeks - Stocks Register

Jul 27, 2024
pulisher
Jul 26, 2024

argenx SE returns to growth driven by Vyvgart, H.C. Wainwright raises shares PT - Investing.com

Jul 26, 2024
pulisher
Jul 26, 2024

argenx shares target lifted on revenue growth prospects - Investing.com

Jul 26, 2024
pulisher
Jul 26, 2024

Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates - Morningstar

Jul 26, 2024
pulisher
Jul 25, 2024

Earnings call: Argenx reported an operating income of $489 million - Investing.com India

Jul 25, 2024
pulisher
Jul 25, 2024

Earnings call: Argenx reported an operating income of $489 million - Investing.com

Jul 25, 2024
pulisher
Jul 24, 2024

argenx ADR Getting Closer To Key Technical Benchmark - Investor's Business Daily

Jul 24, 2024
pulisher
Jul 23, 2024

Oppenheimer upgrades argenx stock rating on CIDP indication - Investing.com

Jul 23, 2024
pulisher
Jul 22, 2024

Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com

Jul 22, 2024
pulisher
Jul 22, 2024

Truist highlights argenx innovative pipeline as stock catalyst - Investing.com India

Jul 22, 2024
pulisher
Jul 22, 2024

Truist highlights argenx innovative pipeline as stock catalyst - Investing.com

Jul 22, 2024
pulisher
Jul 18, 2024

argenx SE stock target lifted with Buy rating on growth outlook - Investing.com

Jul 18, 2024
pulisher
Jul 17, 2024

Scotiabank holds argenx at Sector Perform with $416 target - Investing.com

Jul 17, 2024
pulisher
Jul 16, 2024

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Business Wire

Jul 16, 2024
pulisher
Jul 16, 2024

argenx and Zai Lab Announce Approval of Efgartigimod Alfa - GlobeNewswire Inc.

Jul 16, 2024
pulisher
Jul 15, 2024

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Yahoo Finance

Jul 15, 2024
pulisher
Jul 13, 2024

Fund managers' favourite health stocks - Investors Chronicle

Jul 13, 2024
pulisher
Jul 12, 2024

Barclays maintains Equalweight on argenx stock - Investing.com

Jul 12, 2024
pulisher
Jul 12, 2024

Barclays maintains Equalweight on argenx stock - Investing.com India

Jul 12, 2024
pulisher
Jul 12, 2024

Jefferies lifts Agnico-Eagle Mines shares target amid rising gold prices By Investing.com - Investing.com UK

Jul 12, 2024

Argen X Se Adr Stock (ARGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$122.68
price up icon 2.40%
$267.99
price down icon 0.57%
$246.04
price up icon 5.31%
$60.20
price down icon 1.42%
$355.93
price up icon 1.67%
Cap:     |  Volume (24h):